The authors concluded that there was limited evidence for the potential efficacy of atypical antipsychotics on global post traumatic stress disorder symptoms and individual post-traumatic stress disorder symptoms cluster (in particular intrusion) compared with placebo. The authors' conclusions were appropriately cautious given the small number of diverse trials included.
Results of the review
Seven RCTs were included in the review (n=192 patients, sample size 15 to 65). The authors described the trials as double blinded in the review title and abstract but there was no mention of blinding in the text of the paper. It was noted that there were discrepancies between values given in the text and those shown in the figures. The values reported below are those given in the text.
Primary outcome: Atypical antipsychotics were associated with a statistically significant greater mean change in Clinician Administered PTSD Scale (CAPS) total score than placebo, favouring atypical antipsychotics over placebo (SMD -0.45, 95% CI -0.75 to -0.14; six RCTs); no significant heterogeneity was found.
Secondary outcomes: Atypical antipsychotics were associated with a statistically significant greater mean change in CAPS overall subscore (-0.27, 95% CI -0.47 to -0.07; four RCTs) and CAPS subscore of intrusion (SMD -0.37, 95% CI -0.71 to -0.03; four RCTs) compared to placebo.
There was no difference between atypical antipsychotics and placebo in terms of reported patient response rates as measured by CGI-I scores (CAPS subscore for avoidance, CAPS subscore for hyperarousal, drop-outs due to any reason, and drop-outs due to adverse events. However, it was noted that there was statistically significant heterogeneity for hyperarousal (I 2 =70.2%).
Atypical antipsychotics were also associated with a statistically significant greater mean change in weight compared to placebo (SMD 0.92 lbs, 95% CI 0.27 to 1.58; three RCTs). However there was evidence of statistically significant heterogeneity (I 2 =89.8%). The removal of one trial resulted in the removal of heterogeneity (I 2 =0%) and an even greater mean change weight (SMD 2.58 lbs, 95% 1.60 to 3.57; two RCTs).
Authors' conclusions
There was limited evidence for the potential efficacy of atypical antipsychotics on global post-traumatic stress disorder symptoms and individual post-traumatic stress disorder symptoms cluster (in particular intrusion) compared with placebo.
CRD commentary
This review addressed a clear research question and was supported by adequate inclusion criteria. The search strategy was adequate, but it was limited to published peer-reviewed articles in English only, which increased the risk of both language and publication bias. Data extraction was performed by one reviewer and checked by a second, which reduced the risk of reviewer error and bias in this review process.
There was no assessment of trial quality, which meant that the reliability of the evidence presented could not be determined. The authors acknowledge there was possible clinical heterogeneity among trials causing different treatment effect, but the influence of potential modifiers was not explored.
The authors' conclusions were appropriately cautious given the small number of diverse trials included.
Implications of the review for practice and research
Practice: The authors stated that the clinical significant of the results presented should be carefully interpreted and translated into clinical practice.
Research: The authors stated that there is a need for adequately powered, well designed RCTs that evaluate atypical antipsychotics in settings and populations that reflect real clinical practice. Future studies should compare the efficacy and safety of atypical antipsychotics used in combination with first-line treatments for PTSD, and evaluate these treatments for patients with both combat and non-combat PTSD.
